Core Viewpoint - TATA Health has successfully met all resumption guidelines and will resume trading on the Hong Kong Stock Exchange on December 1, 2025 [1] Group 1 - The company has announced to its shareholders and potential investors that it has fulfilled all requirements for resumption [1] - Trading of the company's shares has been suspended since April 0, 2024, at 9:00 AM [1] - The application for resumption of trading has been submitted to the Stock Exchange [1]

應本公司要求，股份已於二零二四年四月二日上午九時正起暫停買賣。由於所有 復牌指引均已達成，本公司已向聯交所申請股份自二零二五年十二月一日上午九 時正起於聯交所恢復買賣。 本公告乃由TATA健康國際控股有限公司（「本公司」，連同其附屬公司，統稱「本集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09 條及香港法例第571章證券及期貨條例第XIVA部項下的內幕消息條文（定義見上市 規則）而作出。 達成所有復牌指引 董事會欣然知會其股東及潛在投資者，於本公告日期，本公司已達成所有復牌指 引。 恢復買賣 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） (1)達成所有復牌指引；及 (2)恢復買賣 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 達成所有復牌指引 董事會欣然宣佈，截 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） 內部控制審查的主要發現 及 繼續暫停買賣 本公告乃TATA健康國際控股有限公司（「本公司」，連同其附屬公司，統稱「本集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 13.09(2)(a)條及香港法例第571章證券及期貨條例（「證券及期貨條例」）第XIVA部項 下的內幕消息條文（定義見上市規則）而作出。 茲提述(i)本公司於二零二五年九月十日刊發的截至二零二三年十二月三十一日止年 度的全年業績（「二零二三年全年業績」）公告；及(ii)本公司日期為二零二五年九月 十五日的公告，內容有關聯交所對本公司施加的額外復牌指引（「額外復牌指引公 告」）。除另有界定者外，本公告所用詞彙與二零二三 ...

截至月份: 2025年10月31日 狀態: 新提交 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: TATA健康國際控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | 本月底法定 ...

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: TATA健康國際控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | | 5,000, ...

Core Viewpoint - TATA Health announced the appointment of Xu Jianda as the new Chief Financial Officer, effective October 21, 2025, following the resignation of Lai Wenjing [3][6]. Group 1: Appointment Details - Xu Jianda has over 20 years of experience in accounting, auditing, corporate finance, and IPO consulting [3]. - His previous roles include CFO at various companies, including Next Technology Holdings and Central New Energy Holdings [3][4]. - Xu will receive a monthly salary of HKD 100,000 (approximately RMB 92,000), based on his background, qualifications, and responsibilities [4]. Group 2: Previous CFO Information - Lai Wenjing resigned as CFO effective September 3, 2025, to focus on other work commitments [6]. - Lai has over 15 years of senior financial management experience and was with TATA Health since July 2020 [7][8]. - His annual compensation for 2022 was HKD 432,000 (approximately RMB 396,000) [8][9].

Core Viewpoint - Australian biotech CSL has delayed its planned spin-off of its vaccine division, CSL Seqirus, and cut its earnings forecasts due to a significant decline in U.S. flu vaccination rates, resulting in a share price drop of up to 16.6% [1]. Group 1: Spin-off and Restructuring - CSL had previously announced plans to spin off CSL Seqirus into a listed entity by June 2024 as part of a broader restructuring plan that included cutting 3,000 jobs [1]. - The demerger will now occur when market conditions are favorable for maximizing shareholder value, as stated by the company [7]. Group 2: Earnings Forecasts - The company has revised its full-year revenue guidance to a growth range of 2% to 3%, down from the previous 4% to 5% for the financial year ending in June 2026 [4]. - CSL now expects annual net profit after tax and amortization (NPATA) to increase between 4% and 7%, a reduction from the earlier forecast of 7% to 10% growth on a constant currency basis [5]. Group 3: U.S. Vaccine Market Challenges - CSL's CEO noted a greater-than-expected decline in U.S. influenza vaccination rates, despite a positive recommendation from the U.S. administration and a significant public health impact from infections [3]. - The U.S. vaccine market is facing headwinds, including funding cuts for vaccine research and leadership changes at the CDC, which could further impact vaccination rates [3][4].

Core Viewpoint - TATA Health (01255) announced the appointment of Mr. Zhang Mingqi as the Executive Director and Chief Executive Officer, effective from October 21, 2025 [1] - Mr. Xu Jianda will be appointed as the Chief Financial Officer, also effective from October 21, 2025 [1] Summary by Relevant Sections - **Management Changes** - Mr. Zhang Mingqi transitions from Non-Executive Director to Executive Director and is appointed as CEO [1] - Mr. Xu Jianda is appointed as CFO [1]

Core Viewpoint - TATA Health announced the appointment of Zhang Mingqi as the Executive Director and Chief Executive Officer effective from October 21, 2025, and Xu Jianda as the Chief Financial Officer effective from the same date [1] Group 1 - Zhang Mingqi is transitioning from a non-executive director to an executive director and will also take on the role of CEO [1] - Xu Jianda will be appointed as the Chief Financial Officer [1]

Group 1 - TATA Health (01255.HK) announced the appointment of Zhang Mingqi as Executive Director and CEO effective from October 21, 2025 [1] - Xu Jianda has been appointed as Chief Financial Officer [1]